William Blair analyst Ryan Daniels has maintained their bullish stance on EVH stock, giving a Buy rating on April 28.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ryan Daniels has given his Buy rating due to a combination of factors, primarily focusing on Evolent Health’s financial performance and market position. The company’s recent annual proxy statement indicates that Evolent Health is on track to exceed its first quarter 2025 adjusted EBITDA expectations, with a projected $35 million, surpassing both the guidance midpoint and consensus estimates. This positive outlook is likely contributing to the recent increase in the company’s stock value.
Additionally, the stability in the medical cost trend environment, despite being elevated, particularly in areas such as oncology and cardiology, positions Evolent Health favorably within the value-based care sector. The company’s ability to slightly exceed its revenue bookings target further supports the optimistic view of its business trajectory. These elements combined suggest a promising financial future for Evolent Health, justifying the Buy rating.
In another report released on April 28, JMP Securities also reiterated a Buy rating on the stock with a $13.00 price target.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EVH in relation to earlier this year.